Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02637531
Title A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

melanoma

carcinoma

lung non-small cell carcinoma

Therapies

Pembrolizumab

IPI-549

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UCSD San Diego California 92093 United States Details
UCLA Santa Monica California 90404 United States Details
Hematology Oncology Associates of the Treasure Coast Port Saint Lucie Florida 34952 United States Details
Emory University Atlanta Georgia 30322 United States Details
Massachusetts General Hospital Boston Massachusetts 02116 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
South Texas Accelerated Research and Treatment (START) San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field